BioMérieux S.A Recommends Dividend, Payable on May 17, 2018, Announces Executive Changes
February 28, 2018 at 01:00 am
Share
The Board of Directors bioMérieux S.A. recommend that shareholders at the annual general meeting on May 17, 2018 approve a dividend of 0.34 per share. This would represent a total payout of 40.2 million, to be paid on June 7, 2018 as compared to 39.5 million in 2017.
The company also announced the appointment of Guillaume Bouhours as corporate vice-president and chief financial officer and a member of its executive committee. He will take over from Claire Giraut, who has decided to retire, and will head up the same departments, namely Finance, Purchasing and Information Systems. Guillaume Bouhours was previously Group President Access & Mobility at Wabtec. Prior to that, he held the position of Chief Financial Officer for the Faiveley Transport group from 2010 to 2016. The appointment will be effective as from March 2018.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).